It was evaluated in the phase 1 COBALT-RCC trial (NCT04438083) for patients with advanced clear cell renal cell carcinoma (ccRCC) who had previously received checkpoint inhibitors and/or VEGF-targeted therapies. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.